Table 1.
Characteristics | n | MAST (%) | MAST + RT (%) | LUMP (%) | LUMP + RT (%) | p |
---|---|---|---|---|---|---|
Year of study | ||||||
1983–1993 | 56 | 38 (15.0%) | 6 (7.7%) | 7(8.0%) | 5 (5.2%) | 0.012 |
1994–2004 | 209 | 103 (40.6%) | 28 (35.9%) | 29 (33.3%) | 49(51.0%) | |
2005–2016 | 250 | 113 (44.5%) | 44 (56.4%) | 51 (58.6%) | 42 (43.8%) | |
Age (years) | ||||||
≤50 | 93 | 31 (12.2%) | 23 (29.5%) | 17 (19.5%) | 22 (22.9%) | 0.002 |
>50 | 422 | 223 (87.8%) | 55 (70.5%) | 70 (80.5%) | 74 (77.1%) | |
Race | ||||||
Black | 59 | 29 (11.4%) | 8 (10.3%) | 10 (11.5%) | 12 (12.5%) | 0.99 |
White | 433 | 212 (83.5%) | 67 (85.9%) | 73 (83.9%) | 81 (84.4%) | |
Others | 23 | 13 (5.1%) | 3 (3.8%) | 4 (4.6%) | 3 (3.1%) | |
TNM stage | ||||||
I | 95 | 29 (11.4%) | 2 (2.5%) | 34 (39.1%) | 30 (31.3%) | <0.001 |
II | 243 | 131 (51.6%) | 37 (47.4%) | 32 (36.8%) | 43 (44.8%) | |
III | 91 | 47 (18.5%) | 30 (38.5%) | 5 (5.7%) | 9 (0.4%) | |
Unknown | 86 | 47 (18.5%) | 9 (11.5%) | 16 (18.4%) | 14 (14.6%) | |
Tumor stage (n = 429) | ||||||
T1 | 108 | 35 (13.8%) | 4 (5.1%) | 35 (40.2%) | 34 (35.4%) | <0.001 |
T2 | 195 | 105 (41.3%) | 27 (34.6%) | 29 (33.3%) | 34 (35.4%) | |
T3 | 75 | 40 (15.7%) | 20 (25.6%) | 3 (3.4%) | 12 (12.5%) | |
T4 | 51 | 27 (10.6%) | 18 (23.1%) | 4 (4.6%) | 2 (2.1%) | |
Unknown | 86 | 47 (18.5%) | 9 (11.5%) | 16 (18.3%) | 14 (14.6%) | |
Nodal stage | ||||||
N0 | 322 | 156 (61.4%) | 39 (50%) | 62 (71.3%) | 65 (67.7%) | 0.002 |
N1 | 72 | 32 (12.6%) | 22 (28.2%) | 6 (6.9%) | 12 (12.5%) | |
N2 | 21 | 11 (4.3%) | 7 (9.0%) | 1 (1.1%) | 2 (2.1%) | |
N3 | 10 | 6 (2.4%) | 1 (1.3%) | 0 | 3 (3.1%) | |
Unknown | 90 | 49 (19.3%) | 9 (11.5%) | 18 (20.7%) | 14 (14.6%) | |
ER status | ||||||
Positive | 71 | 39 (15.4%) | 11 (14.1%) | 9 (10.3%) | 12 (12.5%) | 0.01 |
Negative | 303 | 139 (54.7%) | 53 (67.9%) | 44 (50.6%) | 67 (69.8%) | |
Unknown | 141 | 76 (29.9%) | 14 (17.9%) | 34 (39.1%) | 17 (17.7%) | |
PR status | ||||||
Positive | 42 | 15 (5.9%) | 11 (14.1%) | 6 (6.9%) | 10 (10.4%) | 0.01 |
Negative | 327 | 159 (62.6%) | 53 (67.9%) | 48 (55.2%) | 67 (69.8%) | |
Unknown | 146 | 80 (31.5%) | 14 (17.9%) | 33 (37.9%) | 19 (19.8%) | |
Grade | ||||||
Well-differentiated | 50 | 22 (33.3%) | 7 (33.3%) | 14 (41.2%) | 7 (24.1%) | 0.29 |
Moderately differentiated | 122 | 66 (66.7%) | 14 (66.7%) | 20 (58.8%) | 22 (75.9%) | |
Poor or undifferentiated | 253 | 117 (70.5%) | 47 (82.5%) | 40 (75.5%) | 49 (73.1%) | |
Unknown | 90 | 49 (29.5%) | 10 (17.5%) | 13 (24.5%) | 18 (26.9%) | |
Chemotherapy | ||||||
Yes | 206 | 86 (33.9%) | 54 (69.2%) | 17 (19.5%) | 49 (51.0%) | <0.001 |
No/unknown | 309 | 168 (66.1%) | 24 (30.8%) | 70 (80.5%) | 47 (49.0%) |
MAST, mastectomy; LUMP, lumpectomy; RT, radiotherapy; ER, estrogen receptor; PR, progesterone receptor.